Comparison · NCT03711279-451ee9b6
SHR-1210 Plus Apatinib vs ADM Plus IFO or IFO Alone: Objective Response Rate (ORR)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. SHR-1210 Plus Apatinib vs ADM Plus IFO or IFO Alone: Objective Response Rate (ORR). Trial comparisons, record NCT03711279-451ee9b6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03711279-451ee9b6
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.22 | 0.128 | 0.352 | wilson | |
| Risk in group 2 | 0.106 | 0.0463 | 0.226 | wilson | |
| Risk difference, group 1 minus group 2 | 0.114 | -0.0375 | 0.259 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.07 | 0.777 | 5.51 | log | |
| Odds ratio, group 1 over group 2 | 2.37 | 0.755 | 7.43 | log | |
| Number needed to treat, for one more participant with the outcome on SHR-1210 Plus Apatinib than on ADM Plus IFO or IFO Alone | 8.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | SHR-1210 Plus Apatinib | SHR-1210 200 mg q3w+ Apatinib 500 mg qd | 11 | 50 | OG000 |
| Group 2 | ADM Plus IFO or IFO Alone | ADM 60 mg/m2 D1 + IFO 2 g/m2 D1-D4 q3w；if the cumulative doses of ADM were beyond 450 mg/m2, the monotherapy of IFO (2 g/m2 D1-D5 q3w) would be used. | 5 | 47 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Objective Response Rate (ORR)
- Description
Baseline to documented disease Remission to study discontinuation, Partial Remission is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 30% decrease in the sum of the beaseline diameter of target lesions.
- Time frame
- From date of randomization until the date of study completion, an average of 1 year, CT was conducted at baseline、weeks 7、13、19 and then every 12 weeks.
- Population
Source ClinicalTrials.gov
Trial
- Title
- A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma
- NCT number
- NCT03711279
- Phases
- PHASE2
- Conditions
- Sarcoma
- Interventions
- SHR-1210 plus Apatinib, ADM plus IFO or IFO alone
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Results first posted
- 2024-02-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03711279?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03711279-451ee9b6